Journal
REGENERATIVE MEDICINE
Volume 16, Issue 4, Pages 405-422Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/rme-2020-0169
Keywords
chimeric antigen receptor T-cell therapy; health technology assessment; innovative payment mechanisms; market access; gene therapy; outcomes-based reimbursement
Categories
Ask authors/readers for more resources
Innovative reimbursement mechanisms are increasingly used for gene therapies in Europe, while the usage is more limited in the USA. Decision makers in different countries face varying incentives and challenges in managing uncertainties around the long-term therapeutic potential of gene therapies.
Innovative reimbursement mechanisms have long been considered potential solutions to the data uncertainty associated with one-off, high-value gene therapies that have long-term therapeutic potential, combined with limited supporting evidence at launch. The launches of increasing numbers of such gene therapies in Europe and the USA in the past 5 years provide valuable exemplars of how innovative reimbursement mechanisms are used by healthcare system decision makers in practice. This review details the use of such reimbursement schemes for recently launched gene therapies in key European countries and the USA, and shows that they are more widespread in Europe than in the USA. Although innovative payment schemes are increasingly used across countries, differences in healthcare system structures (e.g., single- vs multi-payer systems) and willingness to pay mean that decision makers in different countries have different incentives to manage uncertainties around long-term, real-world product value.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available